Trial Access, Opportunity Gaps, and Better Evidence: This Week’s Public Health Signals
This week’s research paints a clear picture of how health systems, policies, and everyday opportunities connect. From where clinical trials are located, to how firearm violence clusters around “opportunity,” to how data sharing can multiply what we learn from trials—these findings all point to one theme: equity isn’t only a goal; it’s a design requirement.
Build Your Public Health Issue
Tell us a little about your work, and we’ll build a personalized issue with five things worth knowing.
Clinical trial access isn’t evenly distributed—especially where need is highest
A study in JAMA Network Open looked at where bladder cancer clinical trials are available across the United States. Researchers reviewed trials listed on ClinicalTrials.gov between June 2019 and June 2025. They also compared trial locations with local bladder cancer rates, deaths, and levels of social and economic disadvantage.
The researchers found 436 bladder cancer trials across 713 U.S. counties. But most counties had no access to a trial site. Of the 3,145 counties studied, only 22.7% had at least one trial site. More than three-quarters (77.3%) had none.
Trials were also more common in communities with lower levels of social vulnerability. Counties with the lowest social vulnerability had more than twice the rate of clinical trials compared with the most vulnerable counties.
There was another troubling pattern. Counties with higher bladder cancer death rates actually had fewer clinical trials. Across more than 7,000 trial sites, only 3.2% were located in counties with the highest bladder cancer death rates.
The type of trial also mattered. Pharmaceutical company-sponsored trials were much less likely than academic trials to be located in counties with the highest death rates. Smaller trials with fewer than 100 participants were also less likely to be located in these communities.
Access to medical research can be an important part of access to health care. Clinical trials can give patients access to new treatments and specialized medical care. But this study suggests that many communities facing the greatest burden from bladder cancer have the least access to these opportunities. Decisions about where trials are located and how patients are supported in joining them can determine who benefits from medical research—and who gets left out.
Data sharing can multiply the value of clinical trials
A study in BMJ looked at what happens when clinical trial data are shared with researchers outside the original research team. The researchers examined 336 clinical trials sponsored by Johnson & Johnson. Data from these trials were available to other researchers through the Yale University Open Data Access (YODA) Project, a platform designed to make clinical trial data available for additional research.
Sharing the data led to substantial new research. About 79% of the trials produced at least one additional publication, resulting in 1,167 publications. About 18% of these papers were written by researchers outside the original research teams.
Outside researchers also used the data in different ways. They were more likely to combine data from several studies, develop models to predict health outcomes, and create new statistical methods or algorithms. Their studies also tended to appear in higher-impact journals and received more online attention.
However, greater attention did not always mean greater influence. Studies from outside researchers received slightly fewer academic citations and were less likely to be cited in clinical guidelines or policy documents.
The role of outside researchers also grew over time. By 11 years after the original studies, more than half of the new research using these data was being produced by external researchers.
Clinical trial data can continue producing useful knowledge long after the original study ends. Making data available to other researchers can lead to new questions, new methods, and new discoveries that the original research team may never have explored. But producing more research is only part of the challenge. New findings still need to make their way into clinical guidelines, policies, and everyday health care to improve people’s health.
Opportunity” tracks with school-related firearm incidents
Preventing violence requires more than responding after it happens. It also means addressing the community conditions that may increase the risk of violence. We preach that all the time. A study in the American Journal of Preventive Medicine looked at the connection between neighborhood conditions and gun violence at schools. Researchers examined 444 school-related firearm incidents that occurred between 2015 and 2021. They compared these incidents with the Child Opportunity Index, which measures neighborhood conditions that can affect children’s health and development.
The differences were large. Neighborhoods with the lowest levels of opportunity had more than three times the odds of experiencing a school shooting compared with neighborhoods with the highest levels of opportunity.
Education stood out as especially important. Neighborhoods with the fewest educational opportunities had more than four times the odds of experiencing a school shooting compared with neighborhoods with the greatest educational opportunities. This pattern remained even after researchers accounted for factors such as state gun laws, region, and whether an area was urban or rural.
Overall, school-related gun violence was more common in communities where children had fewer opportunities, especially educational opportunities.
Preventing school gun violence may require looking beyond schools and firearms alone. Investments in education and other community resources could be an important part of prevention. This study cannot prove that low opportunity causes school shootings, but it can help identify communities where additional resources and prevention efforts may be most needed.
Policy and workforce: nurse practitioner authority may shift cancer detection
Some states have laws called “full practice authority.” These laws allow nurse practitioners to provide more services without physician supervision. Researchers compared states before and after they adopted these laws with states that did not. They used national health care data from 2010 to 2019 and examined six cancers: bladder, cervical, lung, lymphoma, melanoma, and prostate cancer.
The results were mixed. After states adopted full practice authority, detection of cervical cancer and melanoma increased, while detection of bladder cancer decreased. Researchers found no significant changes in lung cancer or lymphoma.
Where people lived also mattered. Some of the overall changes were not seen in rural communities. This suggests that expanding what nurse practitioners are allowed to do may not have the same effects everywhere.
Health care policies can affect more than the number of people who have access to care. They may also change when and how diseases such as cancer are detected. Giving nurse practitioners more independence could improve cancer detection in some cases, but the effects appear to depend on the type of cancer and where patients live. More research is needed to understand whether these policies lead to earlier diagnoses and better long-term health outcomes.
The takeaway: equity is built into where trials, data, and prevention efforts land
Across these studies, progress isn’t only about new interventions —> it’s also about distribution (a.k.a. dissemination science). Trial sites can cluster away from high-mortality counties. Data sharing platforms can broaden secondary research, but guideline uptake may lag. Firearm violence risk appears linked to educational opportunity. Workforce policy changes may reshape detection patterns. This week’s message for public health systems is practical: measure where opportunities exist, identify where gaps concentrate, and design policies that deliberately reach communities with the greatest need.
